At a glance
- Originator Asahi Glass; Mitsubishi Pharma Corporation
- Class Heart failure therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 23 Feb 2004 Discontinued - Preclinical for Hypertension in Japan (PO)
- 06 May 2003 Preclinical trials in Hypertension in Japan (PO)
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation